Gilead and LEO Pharma Join Forces to Develop STAT6 Program for Multiple Inflammatory Disorders
Shots:
- Gilead has entered into a strategic collaboration with LEO Pharma to develop the latter’s small molecule oral STAT6 programs targeting various inflammatory disorders
- As per the terms, Gilead secures worldwide rights to develop, manufacture & commercialize LEO’s preclinical STAT6 inhibitors & degrading proteins, with LEO having the option to co-commercialize them for dermatology outside the US. LEO also retains global rights to topical formulations of the inhibitors
- LEO Pharma is entitled for an aggregate of ~$1.7B ($250M upfront) & high single-digit to mid-teens tiered royalties on sales of oral products while Gilead will get high single-digit to mid-teens tiered royalties on sales of topical products
Ref: Gilead | Image: Terray Therapeutics & Gilead
Related News:- Gilead and Terray Therapeutics Partner to Discover and Develop Small Molecules for Various Targets
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
